Several studies have indicated that oxidative stress is a major risk factor for the initiation and progression of neurological disorders like Parkinson's disease (PD) and Alzheimer's (AD). Therefore, reducing oxidative stress appears to be a rational choice for the prevention and reduction in the rate of progression of these neurological disorders. The brain utilizes about 25% of respired oxygen even though it represents only 5% of the body weight. Free radicals are generated during the normal intake of oxygen, during infection, and during normal oxidative metabolism of certain substrates. Although experimental data are consistent in demonstrating the neuroprotective effects of antioxidants in vitro and in animal models, the clinical evidence that antioxidant agents may prevent or slow the course of these diseases is still relatively unsatisfactory, and insufficient to strongly modify clinical practice. In this paper, natural possible substances that could be added to a beverage to prevent or decrease the developing of neurodegenerative diseases are reviewed.
Introduction
The global functional foods market continues to be a dynamic and growing segment of the food industry. Rapid growth will continue for several years and taper off by 2010, when functional foods are expected to represent five percent of the total global food market. Functional foods have experienced great success, emerging from a niche market to a mainstream market category. As the market has matured and expanded, large food companies and government regulators have become key players in the global functional foods marketplace.
Functional drinks are gaining in popularity worldwide because consumers value the added health benefit. Market Development: European Compound Annual Growth Rate 2002-2007: 7.9%. Still fruit juice drinks can also be enriched with functional ingredients. "Classic functionals" (for example, vitamins A, C and E or minerals such as calcium and magnesium), "new age functionals" (such as ginseng, ginkgo or green tea) or "true functionals", which can include soy and omega-3 fatty acids, are ingredients with scientifically verifiable health-promoting effects.
The most important contributor to the success of functional drinks is their excellent flavor, which is a critical factor in repeat buying. In this paper possible substances that could be added to a beverage for prevent or decrease the developing of neurodegenerative diseases are reviewed.
Oxidative stress in the neurodegenerative disease
It is widely accepted that oxidative stress increases with age, and that age is a major risk factor for several neurodegenerative diseases such as Parkinson's disease (PD) and Alzheimer's disease (AD). An inbalanced overproduction of reactive oxygen species can induce neuronal damage, leading to neuronal death by necrosis or apoptosis [1] . Oxidative stress is mechanistically and chronologically associated with other key features of Alzheimer disease, namely, metabolic, mitochondrial, metal, and cell-cycle abnormalities. Several lines of evidence now indicate that aggregation of amyloid-beta and tau is a compensatory response to underlying oxidative stress [2] . This raises the possibility of prevent, or at least slowing down, the progression of neurodegenerative diseases by the use of antioxidants.
Free radicals and other so-called 'reactive species' are constantly produced in the brain in vivo. Some arise by 'accidents of chemistry', an example of which may be the leakage of electrons from the mitochondrial electron transport chain to generate superoxide radical (O 2 -). Others are generated for useful purposes, such as the role of nitric oxide in neurotransmission and the production of Oby activated microglia. Because of its high ATP demand, the brain consumes oxygen rapidly, and is thus susceptible to interference with mitochondrial function, which can in turn lead to increased O 2 formation.
The brain contains multiple antioxidant defences, of which the mitochondrial manganese-containing superoxide dismutase and reduced glutathione seem especially important. Iron is a powerful promoter of free radical damage, able to catalyse generation of highly reactive hydroxyl, alkoxyl and peroxyl radicals from hydrogen peroxide and lipid peroxides, respectively. Although most iron in the brain is stored in ferritin, catalytic iron is readily mobilised from injured brain tissue [1] .
Increased levels of oxidative damage to DNA, lipids and proteins have been detected by a range of assays in post-mortem tissues from patients with PD, AD and amyotrophic lateral sclerosis, and at least, some of these changes may occur early in disease progression.
The accumulation and precipitation of proteins that occur in these diseases may be aggravated by oxidative damage, and may in turn cause more oxidative damage by interfering with the function of the proteasome. Indeed, it has been shown that proteasomal inhibition increases levels of oxidative damage not only to proteins but also to other biomolecules. Hence, there are many attempts to develop antioxidants that can cross the blood-brain barrier and decrease oxidative damage [3] . Little is known about the impact of dietary antioxidants upon the development and progression of neurodegenerative diseases, especially of AD. Although experimental data are consistent in demonstrating the neuroprotective effects of antioxidants in vitro and in animal models, the clinical evidence that antioxidant agents may prevent or slow the course of this disease is still relatively unsatisfactory, and insufficient to strongly modify clinical practices [1] .
Much of the evidence from early studies in many ways reflects a pattern of dietary associations very similar to more established dietary risk factors for cardiovascular diseases, such as heart disease. Thus, patients who adopt these dietary practices will reduce their risk for heart disease and may also curtail their risk of developing AD.
Although some antioxidants have been shown to reduce the incidence of AD, the magnitude of the effect may be modified by individual factors such as genetic predisposition (e.g. apolipoprotein E genotype) and habitual behaviours. Because caloric restriction, exercise, and intellectual activity have been experimentally shown to promote neuronal survival through enhancement of endogenous antioxidant defenses, a combination dietary regimen of low total calorie and rich antioxidant nutrients joint to physical maintenance and intellectual activities, may ultimately prove to be one of the most effective strategies for AD prevention [2] .
The fact that clinical symptoms PD and AD appear only when a significant number of neurons are losts, supports the value of plasticity of the neurons in maintaining normal brain function. Supplementation with antioxidants vitamin A, C, and E, natural βcarotene, co-enzyme Q10, α-lipoic acid, may reduce the rate of loss of neurons [4] .
In order to investigate the effect of antioxidants in an animal model of PD and AD, it is essential to study whether antioxidant supplementation can increase brain levels of antioxidants and whether antioxidants can prevent or decrease the develoment of neurodegenerative diseases.
Tentative ingredients for functional drinks in neurodegenerative diseases
Vitamin E and C: Vitamin E is the collective name for a set of 8 related tocopherols and tocotrienols, which are fat-soluble vitamins with antioxidant properties. Of these, α-tocopherol has been the most studied as it has the highest bioavailability, with the body preferentially absorbing and using this form [5] .
α-Tocopherol is the most important lipid-soluble antioxidant, and it protects cell membranes from oxidation by reacting with lipid radicals produced in the lipid peroxidation chain reaction. This would remove the free radical intermediates and prevent the oxidation reaction from continuing. The oxidised αtocopheroxyl radicals produced in this process may be recycled back to the active reduced form through reduction by other antioxidants, such as ascorbate, retinol or ubiquinol [6] . The regeneration of αtocopherol from its tocopheroxyloxyl radical greatly enhances the turnover efficiency of α-tocopherol in its role as a lipid antioxidant.
Vitamin E's biological activity can be seen and understood in the light of protection of polyunsaturated fatty acids and the membrane qualities (fluidity, phase separation, and lipid domains) that polyunsaturated fatty acids bring about [6] .
Major sources of α-tocopherol in the diet include vegetable oils (olive, sunflower, and saffflower oils), nuts, whole grains, and green leafy vegetables. All eight forms of vitamin E (α, β, γ and Δ-tocopherols and tocotrienols) occur naturally in foods but in varying amounts (Table 1) . Natural vitamin E has roughly twice the availability of synthetic vitamin E. The D-α-tocopherol in our food, the natural form, is a single entity, in other words all the molecules are identical. By contrast, the synthetic DL-α-tocopherol is a mixture of 8 different molecular entities, known as stereoisomers. Of these 8, only 1 is identical to the natural form. The other 7 do not exist in nature. One mg of natural vitamin E is equivalent to approximately 1.5 IU of D-α-tocopherol, whereas 1 mg of the synthetic form is approximately equivalent to 1 IU of DL-α-tocopherol [7] .
Nuts, whole grains, green leafy vegetables and olive oil, are included in the mediterranean diet. The problem is that it is not easy to get large amounts of E from food.
Vitamin C is purely the L-enantiomer of ascorbate; the opposite D-enantiomer has no physiological significance. When L-ascorbate, which is a strong reducing agent, carries out its reducing function, it is converted to its oxidized form, L-dehydroascorbate. L-dehydroascorbate can then be reduced back to the active L-ascorbate form in the body by enzymes and glutathione [8] .
All fruits and vegetables contain some amount of vitamin C. Foods that tend to be the highest sources of vitamin C include green peppers, citrus fruits and juices, strawberries, tomatoes, broccoli, turnip greens and other leafy greens, sweet and white potatoes, and cantaloupe. Other excellent sources include papaya, mango, watermelon, brussels sprouts, cauliflower, cabbage, winter squash, red peppers, raspberries, blueberries, cranberries, and pineapples (Table 2 ) [7, 9] .
Vitamin C is an antioxidant that is believed to have a protective role. Similar to vitamin E, vitamin C may help prevent free radical damage to the brain.
Although many important clinical studies support the role of free radicals in the progression of AD and PD, the use of a single antioxidant, vitamin C, may not be optimal for quenching all the various types of free radicals that are produced in the brain.
Vitamin C is necessary to protect cellular components in aqueous environments, whereas carotenoids, vitamins A and E protect cellular components in non-aqueous environments. In addition, vitamin C is necessary for the activity of tyrosine hydroxylase, which is the rate-limiting enzyme in the synthesis of catecholamines. Vitamin C also plays an important role in maintaining cellular levels of vitamin E by recycling the vitamin E radical [10, 11] . Also, oxidative damage produced by vitamin C (oxidized adenine nucleotides) could be protected by vitamin E. Epidemiologic studies have suggested that intake of antioxidant nutrients may be associated with a reduced risk of developing Alzheimer`s disease.
Vitamin E can block hydrogen peroxide production and the resulting cytotoxicity. Vitamin E reduces β-amyloid-induced cell death in rat hippocampal cell cultures and PC12 cell and attenuates excitatory amino acid-induced toxicity in neuroblastoma cells [12] . Arlt et al. (2002) [13] suggest that the combination of vitamin C and E has been shown to efficiently inhibit lipoprotein oxidation in plasma and cerebrospinal fluid following oral supplementation. In addition, some studies have documented low levels of vitamin E in cerebrospinal fluid of patients with AD [14] .
Vitamin E supplementation has been shown to reduce cognitive impairment in rats, probably due to reduced oxidative stress in the cerebral cortex and hippocampus [15] . Other authors have described that dietary supplementation with vitamin E and vitamin C protected rats (rat model of PD) against 6hydroxydopamine-induced striatal damage [16, 17] .
A large placebo-controlled intervention trial in individuals with moderate neurological impairment found that supplementation with 2,000 IU of synthetic α-tocopherol daily for two years (equivalent to 900 mg/day of D-α-tocopherol) significantly slowed progression of Alzheimer's dementia [18] . Grundman, (2000) [19] reported that vitamin E may slow functional deterioration leading to nursing home placement in patients with moderately advanced AD.
In contrast, a placebo-controlled trial in patients with mild cognitive impairment reported that the same dosage of vitamin E did not slow progression of AD over a 3-year period [10] . These results agree with those reported by Isaac et al., (2008) [20] who reported that there is no evidence of efficacy of vitamin E in the prevention or treatment of people with AD or mild cognitive impairment (MCI).
Literature Data indicate that lysosomes play a key role in AD, in preventing the formation of amyloid deposits and senile plaques, and vitamin C improves lysosomal functions of human brain astrocytes and thereby preserves cellular function [21] .
Early stage PD is referred to as a condition where no L-dopa therapy is required. Therefore, any significant extension of this time interval would be an important contribution to the management of PD. Vitamin C is recommended for early stage PD and AD is 500 mg/day [4, 6] .
In a preliminary study, supplementation with vitamin C (3,000 mg/day) and vitamin E (3,000 I.U/day) increased the time interval for requiring L-dopa therapy by about 2-4 years in 75% of patients when compared to historical controls; however, 16% of patients on vitamin therapy did not require L-dopa therapy at the time of writing the manuscript (about 8 years ago) [12, 17] .
After AD, vascular dementia (VD) is the most common type of dementia in the United Stated. A case-control study examining risk factors for VD in elderly Japanese-American men found that supplemental vitamin E and vitamin C intake was associated with a significantly decreased risk of vascular and other types of dementia but not Alzheimer's dementia. Among those without dementia, vitamin E supplement intake was associated with better scores on cognitive tests. Although these findings are promising, further studies are required to determine the role of αtocopherol supplementation in the treatment of AD and other types of dementia [22] . Engelhart et al., 2002 [23] in the Rotterdam Study, with a population-based, prospective cohort study conducted in the Netherlands in a total of 5395 participants who, at baseline (1990) (1991) (1992) (1993) , were aged at least 55 years, free of dementia, and non institutionalized and had reliable dietary assessment.
Reported after a mean follow-up of 6 years, that 197 participants developed dementia, of which 146 had AD. When adjustments were made for age, sex, baseline Mini-Mental State Examination score, alcohol intake, education, smoking habits, pack-years of smoking, body mass index, total energy intake, presence of carotid plaques, and use of antioxidant supplements, high intake of vitamin C and vitamin E was associated with lower risk of AD. Among current smokers, this relationship was most pronounced and also was present for intake of β-carotene and flavonoids. The associations did not vary by education or apolipoprotein E genotype. They observed that high dietary intake of vitamin C and vitamin E may lower the risk of AD. These results are in agreement with the ones by Morris et al. 1998 [24] . Morris et al., 2002 [25] carried out a study with 815 residents of 65 years and older, free of AD at baseline and followed up for a mean of 3.9 years, to examine whether intake of antioxidant nutrients, vitamin E, vitamin C, and beta carotene is associated with AD incident. This study suggests that vitamin E from food, but not other antioxidants, may be associated with a reduced risk of AD. Unexpectedly, this association was observed only among individuals without the APOE ε 4 allele.
Pham and Plakogiannis, (2005) [26] showed encourage patients to supplement with vitamin E rich foods. The use of a daily multivitamin, which usually contains 30 UI of α-tocopherol may be beneficial; however, they discourage individual vitamin E supplements that usually contain 400 UI of α-tocopherol.
Boothby and Doering (2005) [27] following a review of the literature, they reported that in the absence of prospective, randomized, controlled clinical trials documenting benefits that outweigh recently documented morbidity and mortality risks, vitamin E supplements should not be recommended for primary or secondary prevention of AD. Although the risks of taking high doses of vitamin C are lower than those with vitamin E, the lack of consistent efficacy data for vitamin C in preventing or treating AD should discourage its routine use for this purpose.
In the same line Fillenbaum et al., (2005) [28] in a study to determine whether supplement use of vitamins C and/or E in a community-based sample of older African American and white individuals delayed incident dementia or AD reported that the use of vitamins C and/or E did not delay the incidence of dementia or AD. Etminan et al. (2005) [29] studied the effect of vitamin C, vitamin E, and β-carotene intake on the risk of PD. They did a systematic review and metaanalysis of observational studies published between 1966 and March 2005. They found that dietary intake of vitamin E protects against PD. This protective influence was seen with both moderate intake and high intake of vitamin E, although the possible benefit associated with high intake of vitamin E was not significant. The studies did not suggest any protective effects associated with vitamin C or β-carotene. They concluded that dietary vitamin E may have a neuroprotective effect attenuating the risk of PD [21, 29] .
As a conclusion it seems that more research is needed to identify the role of vitamin E and C, if any, in management of cognitive impairment.
Polyphenols: flavonoids, curcumin and resveratrol
Polyphenols are the most abundant antioxidants in the diet. Indeed, fruits, vegetables, beverages (tea, wine, and juices), plants, and some herbs are loaded with powerful antioxidant polyphenols. Phenolic compounds have been receiving increasing interest from consumers and manufacturers because of the numerous epidemiological studies that suggest associations between consumption of polyphenol-rich foods or beverages and the prevention of certain chronic diseases such as cancers and cardiovascular diseases.
Furthermore, in the past 10 years, research on the neuroprotective effects of dietary polyphenols has developed considerably. These compounds are able to protect neuronal cells in various in vivo and in vitro models through different intracellular targets. However, it is not at all clear whether these compounds reach the brain in sufficient concentrations and in a biologically active form to exert beneficial effects [30] .
It has become clear that the mechanisms of action of these polyphenols go beyond their antioxidant activity and the attenuation of oxidative stress. Therefore, there is a need of more research on their intracellular and molecular targets as special pathways underlying distinct polyphenol-induced neuroprotection.
Flavonoids: Polyphenols can be divided into two categories: flavonoids and non flavonoids. The flavonoids may be divided into different subclasses according to the degree of oxidation of the heterocyclic ring: anthocyanins (source: red, blue and purple berries, red and purple grapes, red wine, cherry, rhubarb), flavanols (source: green and black tea, chocolates, grapes, berries, apples), flavonols (source: red cabbage, yellow onion, curly pale, cherry, tomato, broccoli, blueberry, apricot, apple, black grappe, green and black tea), flavanones (source: citrus fruits and orange), flavones (source: parsley, celery, thyme, hot pepper), isoflavones (source: soybeans, soy foods, legumes) and proanthocyanidins (source: chocolate, apples, berries, red grapes, red wine). Quercetin, present in many fruits, vegetables and beverages, is the main flavonol in our diet (its mean intake is around 16 mg/day). Catechins are abundant in tea and infusion of green tea could contain 1g/L catechins, whereas in black tea their content is reduced to about half of this value due to their oxidation into more complex polyphenols during fermentation [31] .
The maximal plasma concentrations of flavonoids are quite low, usually not more than 1 micromol/L, with a maximum level attained 1-2 h after ingestion. Therefore, the maintenance of a high concentration in plasma requires repeated ingestion of the polyphenol over time [31] . The active compounds may not be the native flavonoid polyphenolics found in food, which are most often tested in in vitro studies; they are more likely to be metabolites [32] . Except catechins, they are hydroxylated, methoxylated and/or glycoxylated derivatives [33, 34] . Major differences in bioavailability are now well established, and the influence of structural factors is better understood [35] . Flavonoids are extensively conjugated in the body, and nonconjugated metabolites most often account for a minor fraction of the circulating metabolites. Only some polyphenols are currently known regarding the biological activities of these conjugated metabolites [36] .
The absorption of flavonoids also depends on the molecular weight. Because of their large molecular weight and their hydrosolubility, proanthocyanidins are poorly absorbed in the small intestine and rapidly metabolized and eliminated [35] . Studies have shown that of ingested quercetin < 2% showed up in plasma. However, it is possible that quercetin remains in the epithelial cells of the gut, exerting its antioxidant effects locally to protect against colon cancer [37] . It also indicates that systemic bioavailability of quercetin is low and that bioavailability to the brain is almost negligible.
Moreover glucuronides of isoflavones and epicatechin were shown to have much weaker estrogenic activity and provided no protection against oxidative stress in cells grown (such as neurons) in vitro [38, 39] .
Although numerous studies have reported flavonoidmediated neuroprotection, there is little information about the interaction of flavonoids or their metabolites with the blood-brain barrier (BBB). The flavonoid epigallocatechin gallate, that it is polar, has been reported to enter the brain after a gastric administration of [H 3 ] epigallocatechin gallate [40] . The citrus flavonoids naringenin and hesperidtin readily cross the BBB, whereas the less lipophilic glucuronide or glycoside conjugates have greater difficulty [41] . A protective association between flavonoid intake and dementia was found in the socalled PAQUID study, a 5 and 10 year follow-up study of a cluster sample of 1640 subjects of France. This study suggested that an average intake of 14.3±5.8 mg/day of dietary flavonoid was associated with less cognitive decline in subjects aged 65 years or older [42] .
In the same line, green tea is rich in catechin flavonoids, although there is no significant outcome relative to tea consumption in AD case control, there are several in vitro studies showing that green tea extract may protect neurons from Aβ-induced damage [43] .
Berries are rich sources of anthocyanins, proanthocyanidins and other flavonoids. In a recent study, the data suggest that blueberry extract supplementation might prevent cognitive and motor deficits through various neuronal signalling pathways [44] . These results are in agreement with Wang et al. (2008) [45] that have observed that Cabernet Sauvignon exerts a beneficial effect by promoting nonamyloidogenic processing of amyloid precursor protein, which ultimately prevents the generation of Aß peptides. A commercially available grape seed polyphenolic extract significantly attenuated AD-type cognitive deterioration and reduced cerebral amyloid deposition.
In fact, moderate wine consumption, within the range recommended by the FDA dietary guidelines of one drink per day for women and two for men, may help reduce the relative risk for AD clinical dementia.
Several dietary supplements with either spinach or strawberry extracts have also been reported to reduce some neurological deficits in aged animal models [46] .
It may be possible that dietary polyphenols continuously participate in the regulation of cellular functions independent of their antioxidant properties.
In addition, we cannot exclude the possibility that polyphenolic compounds may regulate the expression of some genes coding for antioxidant enzymes and thus help the neural cells to cope with increased oxidative stress [31] .
Clinical and epidemiological studies suggest that the consumption of flavonoids and polyphenols from fruits, vegetables or beverages could reduce the risk of AD. However, the relationship between polyphenol consumption and risk of dementia needs further investigations.
Curcumin:
The rhizomes (i.e., underground rootlike stems bearing both roots and shoots) of tropical ginger and turmerics (e.g., Zingiber and Curcuma spp.) contain curcumin, the yellow curry spice which has an extensive history as a food additive and herbal medicine throughout Asia, but especially in India ( Figure 1 ). Curcumin exerts potent antioxidant activity, the properly that lead to its early use as a food preservative.
Curcumin has specific anti-amyloidogenic effect.
There is convergent evidence that toxic effects of Aß on normal cellular function and viability underlay the pathogenesis of AD.
Curcumin is a powerful anti-inflammatory agent, potentials the anti-atherogenic effect of α−tocopherol, and decreases total blood lipid peroxides as well as HDL and LDL lipid peroxidation [47] .
Researchers have demonstrated that curcumin inhibits lipoxygenase-5 and cyclooxygenase 2, enzymes that are responsible for the synthesis of the pro-inflammatory leukotrienes, prostaglandins and thromboxanes, so it has platelet aggregation inhibiting properties [48] . Ono et al., 2006, [49] performed an in vitro study in which they measured the effects of curcumin on formation of Aß fibrils from Aß 1-40 and Aß 1-42 peptides. They found that curcumin inhibited the formation and extension of Aß fibrils and destabilized preformed Aß fibrils in a dose dependent fashion at a range between 0.1 and 1 micro-molar concentration. Curcumin could be a molecule for the development of therapeutics for AD.
Resveratrol: Resveratrol, a red wine polyphenol, is known to protect against cardiovascular diseases and cancers, as well as to promote antiaging effects in numerous organisms. It also modulates pathomechanisms of debilitating neurological disorders such as stroke, ischemia, and Huntington's disease. The role of resveratrol in AD is still unclear, although some recent studies on red wine bioactive compounds suggest that resveratrol modulates multiple mechanisms of AD pathology. Emerging literature indicates that mechanisms of aging and AD are intricately linked and that these mechanisms can be modulated by both calorie restriction regimens and calorie restriction mimetics, the prime mediator of which is the SIRT1 protein, a human homologue of yeast silent information regulator (Sir)-2, and a member of NAD+-dependent histone deacetylases. Calorie restriction regimens and calorie restrictionmimetics trigger sirtuins in a wide variety of organisms, ranging from bacteria to mouse. In a mouse model of Huntington's disease, resveratrolinduced SIRT1 was found to protect neurons against ployQ toxicity and in Wallerian degeneration slow mice, resveratrol was found to protect the degeneration of neurons from axotomy, suggesting that resveratrol may possess therapeutic value to neuronal degeneration [50] . Sharma and Gupta, 2002 [51] in a cognitive model of AD in rats, demonstrated the effectiveness of resveratrol in preventing the cognitive deficits as well as the oxidative stress in the treatment of neurodegenerative diseases such as AD. Blanchet et al., 2008, [52] analysed the protective effect of a diet rich in resveratrol against 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP) -induced neuronal death. Male mice were kept on a phytoestrogen-free diet, supplemented or not with 50 or 100 mg/kg/day of resveratrol for 1 or 2 weeks, after which MPTP was injected intraperitoneally.
They demonstrated that mice treated with resveratrol prior to MPTP administration showed more abundant TH-immunopositive neurons than mice given only MPTP, indicating that resveratrol protects nigral neurons from MPTP insults. These data revealed that resveratrol can counteract the toxic effects of the neurotoxin MPTP and, as such, it may be regarded as a powerful molecule for complementary neuroprotective therapy.
Resveratrol has been shown to attenuate betaamyloid induced cytotoxicity, apoptotic features, and intracellular ROS accumulation. Specifically, it has been shown to inhibit beta-amyloid peptides formation and destabilize preformed Abeta [53] . Ono et al., (2003) [54] , have documented the fact that Abeta and oxidative brain lipoproteins can synergistically enhance oxidative damage in neurons and antioxidants such as resveratrol can ameliorate this damage. Resveratrol could be a key molecule for the development of preventives and therapeutics for AD.
Resveratrol also maintains cell viability and exerts an antioxidative action by enhancing the intracellular free radical scavenger glutathione. Savascan et al., 2003 suggest that red wine may be neuroprotective through the actions of resveratrol [55] .
Mineral antioxidants: selenium and zinc
Selenium: Selenium is a trace mineral that is essential to good health but required only in small amounts Selenium is incorporated into proteins to make selenoproteins, which are important antioxidant enzymes.
Deficiency of the element in animals makes them susceptible to injury by certain types of oxidative stress. Deficiencies of glutathione are seen in conditions of oxidative stress, including PD and AD.
Glutathione deficiencies are also described in toxicity issues such as an overdose of medications, decreased liver function or in cases where overall nutrients are lacking in the diet as in some eating disorders and malnutrition. A potent antioxidant, glutathione is produced in the human body from the synthesis of Table 3 : Selected food sources of selenium [7] .
Micrograms (μg)
Percent DV* three key amino acids -cysteine, glycine, and glutamic acid. Nutrients to increase glutathione levels and activity include lipoic acid, vitamins E and C, and selenium.
The selenium content of food is highly variable because it depends so heavily on soil conditions. In fact, some researchers have concluded that it is not possible to create a valid list of foods and their selenium content for this reason. While soil conditions affect plant foods most directly, they also affect animal foods, since most animals depend upon plants for their diet. Natural food sources high in selenium include cereals (egg. corn, wheat, and rice), nuts (brazil nuts and walnuts), legumes (soybeans), animal products (beef, chicken, egg, cheese) and seafood (tuna). Other selenium rich foods are oats, cods and turkey. Brazil nuts are among the very rich sources of selenium. In fact, it is advised to exercise caution with consumption of brazil nuts, as the selenium intake may reach to toxic level (Table 3 ) [7] . Men and women should consume 50 to 200 micrograms of selenium a day [56] .
The selenocysteine-containing form occurred in green algae, diatoms, sea urchin, fish and chicken.
Selenium can be purchased as a dietary supplement in one of two basic forms: chelated or non-chelated.
In the case of selenium, the most common chelates fall into the category of amino acid chelates. The most widely-available are selenomethionine and selenocysteine. Supplemental selenium is also available in non-chelated form, which is the most widely available form, usually as sodium selenate and sodium selenite. Although all forms of selenium described above are fairly well absorbed by the body, some studies show a slight edge to selenomethionine over selenocysteine, selenocysteine over sodium selenate, and sodium selenate over sodium selenite [56] .
Selenium is widely distributed throughout the body, but is particularly well maintained in the brain, even upon prolonged dietary selenium deficiency. Changes in selenium concentration in blood and brain have been reported in AD and brain tumours. The functions of selenium are believed to be carried out by selenoproteins, in which selenium is specifically incorporated as the amino acid, selenocysteine. Several selenoproteins are expressed in brain, but many questions remain about their roles in neuronal function. Glutathione peroxidase has been localized in glial cells, and its expression is increased surrounding the damaged area in PD and occlusive cerebrovascular disease, consistent with its protective role against oxidative damage. Selenoprotein P has been reported to possess antioxidant activities and the ability to promote neuronal cell survival. Recent studies in cell culture and gene knockout models support a function for selenoprotein P in delivery of selenium to the brain. mRNAs for other selenoproteins, including selenoprotein W, thioredoxin reductases (15-kDa selenoprotein) and type 2 iodothyronine deiodinase, are also detected in the brain [57] .
Zinc: Zinc is an essential mineral that is naturally present in some foods, added to others, and available as a dietary supplement. Zinc is involved in numerous aspects of cellular metabolism. It is required for the catalytic activity of approximately 100 enzymes and it plays a role in immune function, protein synthesis, wound healing, DNA synthesis, and cell division. Zinc also supports normal growth and development during pregnancy, childhood, and adolescence and is required for proper sense of taste and smell. A daily intake of zinc is required to maintain a steady state because the body has no specialized zinc storage system [58] . A wide variety of foods contain zinc (Table 4 ) [7] . Oysters contain more zinc per serving than any other food, but red meat and poultry provide the majority of zinc in the American diet. Other good food sources include beans, nuts, certain types of seafood (such as crab and lobster), whole grains, fortified breakfast cereals, and dairy products.
Phytates, which are present in whole-grain breads, cereals, legumes, and other foods bind zinc and inhibit its absorption. Thus, the bioavailability of zinc from grains and plant foods is lower than that from animal foods, although many grain-and plant-based foods are still good sources of zinc [59] . Phytates, which are present in whole-grain breads, cereals, legumes, and other foods bind zinc and inhibit its absorption. [60] . Although the antioxidant properties of zinc were first demonstrated in vitro, there is also clear evidence that zinc functions as an antioxidant in the body. One area of growing interest is the role of zinc as an antioxidant in the central nervous system (CNS), particularly the brain. Compared to other soft tissues, the human brain contains significant amounts of zinc. Among the essential trace elements, zinc is second only to iron in total concentration in the brain. Zinc deficiency has been proposed to lead to nervous system disorders, including mental disturbances, loss of sensory acuity, and impaired cognitive and psychological function. Notably, oxidative stress is associated with the development and progression of several different neuropathologies, including AD, ALS, and PD.
Recent studies examined the role of zinc in maintaining the integrity of the blood brain barrier (BBB), which is the highly specialized blood vessel system of the CNS that serves to protect the brain by excluding toxic agents and other foreign compounds. Alterations or dysfunction of the BBB have been observed in many brain disorders. The investigations have focused on the antioxidant function of zinc that may protect the BBB against oxidative damage. Using magnetic resonance imaging (MRI) they have demonstrated that zinc deficiency in rats dramatically increases the permeability, or leakiness, of the BBB [61] .
Other antioxidants
β-carotene: β-carotene (BC) is more effective in quenching oxygen radicals than most other antioxidants. BC can produce certain effects that cannot be produced by its metabolite vitamin A, and vice-versa. Some antioxidants such as vitamin E are more effective quenchers of free radicals in reduced oxygen pressure. Vitamin C is necessary to protect cellular components in aqueous environments, whereas carotenoids, vitamins A and E protect cellular components in non aqueous environments.
Coenzyme Q 10: Coenzyme Q 10 (CoQ 10 , or ubiquinone) is an endogenous enzyme cofactor, produced in all living human cells and naturally occurring in dietary sources. As a constituent of the proton/electron transport chain, it plays an important role in the energy production within mitochondria. Its position in membranes also allows CoQ 10 to act as a primary scavenger of free radicals, protecting both membrane phospholipids from peroxidation and membrane proteins and mitochondrial DNA from oxidative damage. In addition, it regenerates other antioxidants such as tocopherol and ascorbate. CoQ 10 may also stimulate cell growth and inhibit apoptosis.
Since mitochondrial dysfunction is associated with PD and other neurodegenerative diseases, and CoQ 10 (coenzyme Q 10 ) and nicotinamide adenine dinucleotide (reduced form NADH) are needed for generation of ATP by mitochondria, it is essential to use this antioxidant among the high risk populations.
CoQ10, serves as the electron acceptor for complexes I and II of the mitochondrial electron transport chain and acts as an antioxidant, has the potential to be a beneficial agent in neurodegenerative disease in which there impaired mitichondrial function and/or excesive oxidative damage.
A decrease in CoQ 10 levels occurs with genetic mutations, aging, cancer, and the intake of statins, and altered levels are seen in diabetes mellitus, cardiovascular disorders, AD, and other neurodegenerative disorders. Recent clinical trials suggest that large doses of supplements CoQ10 can slow the functional decline in these neurodegenerative diseases [62] .
Omega-3 fatty acids:
Interest in omega-3 fatty acids can be traced to observational studies of Greenland Inuits conducted in the late 1970s. The low occurrence of coronary heart disease (CHD) in this Eskimo population was attributed to their traditional diet of marine animals and fish. Such food sources are rich in omega-3 fatty acids called eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [63] . Omega-3 fatty acids are probably known best for their heart health benefits. However, a growing body of research suggests that omega-3 fatty acids may provide benefits beyond reducing the risk of cardiovascular disease, such as lowering the risk of developing certain cancers, neurological disorders, and complications from metabolic syndrome and diabetes. Improved bone health among older adults; healthy pregnancy outcomes; and good visual acuity and cognitive development among infants have also been attributed to fatty acids in some studies [64, 65] .
Understanding the role of omega-3 fatty acids in health begins with knowledge of the chemical makeup of certain fatty acids. Omega-3 fatty acids are long-chain polyunsaturated fatty acids (LC-PUFAs) that include alpha-linolenic acid (ALA), EPA, and DHA. The human body cannot synthesize ALA, making it an "essential fatty acid", thus it needs to be obtained from dietary sources. ALA can be converted by the body into EPA and DHA, but the amounts are not significant (less than five percent). Unfortunately, it is now well-known that these enzymes do not function optimally in many people, and, consequently, only a small amount of ALA consumed in the diet is converted to EPA, DHA, and ultimately to the anti-inflammatory prostaglandins. The conversion of ALA to EPA and DHA involves a series of chemical reactions. One of the first reactions in this series is catalyzed by the enzyme delta-6 desaturase. Further down the line is a reaction that is catalyzed by the enzyme delta-5 desaturase.
To increase the activity of your desaturase enzymes, be sure that your diet includes a sufficient amount of vitamin B6, vitamin B3, vitamin C, magnesium and zinc. In addition, limit your intake of saturated fat and partially hydrogenated fat, as these fats are known to decrease the activity of delta-6 desaturase. Also, to be on the safe side, consider including a direct source of EPA and DHA in your diet, such as wild-caught salmon, halibut, or tuna [66] .
Omega-6 fatty acids comprise another class of LC-PUFAs. Major food sources of each type of LC-PUFA are provided in Table 5 .
The US Food and Drug Administration (FDA) has allowed a number of fish and algal oils to be generally recognized as safe (GRAS) for food fortification. Algal oil is useful for those concerned with fish consumption and those who do not include fish in their diet, such as some vegetarians. Examples of foods being fortified with omega-3 fatty acids include milk-based products, juices, table spreads, salad dressings, sauces, breakfast cereals, baked goods, infant formulas, baby foods and juices, among others. Omega-3 fatty acids in the form of dietary supplements are also available [67] .
LC-PUFAs comprise about 20 percent of the brain's dry weight and are critical for healthy brain development and function. A deficiency of omega-3 fatty acids may result in neurologic abnormalities and growth retardation [68] .
Epidemiologic studies suggest that omega-3 fatty acids reduce the risk of CVD by decreasing the risk of arrhythmias and thrombosis, decreasing triglyceride levels and the rate of growth of atherosclerotic plaques, improving endothelial function, and reducing inflammatory responses [69, 70] .
The American Heart Association (AHA) [69] recommends that all adults eat fish (in particular fatty fish) at least twice a week. For patients with high levels of triglycerides, the AHA recommends EPA and DHA supplements, e.g. fish oil, of two to four grams a day. Patients taking more than three grams of these fatty acids from supplements should do so only under the care of a physician (Table 6 ). Ongoing study of optimal amounts of polyunsaturated fats in the diet has led to questioning whether a balance of omega-6 and omega-3 fatty acids is necessary for maximizing the benefits of these fats. However, there is limited data to support that lowering intake of omega-6 fatty acids, reduces risk for CHD. Rather than the ratio, the more important issue to focus on may be to ensure an adequate intake of omega-3 fatty acids to maintain cardiovascular health [71] . There have been limited peer reviewed reports of intervention studies. Studies in animals clearly show that oral intake of docosahexaenoic acid (DHA) can alter brain DHA concentrations and thereby modify brain functions. This provides us with an opportunity to use DHA as a nutraceutical or pharmaceutical tool in brain disorders such as AD and PD. Most of the published epidemiological studies are consistent with a positive association between high reported DHA consumption or high DHA blood levels and a lower risk of developing AD later in life. Such observations have prompted the investigation of DHA in three different transgenic models of AD. These analyses show that animal models of AD are more vulnerable to DHA depletion than controls and that DHA exerts a beneficial effect against pathological signs of AD, including Aβ accumulation, cognitive impairment, synaptic marker loss, and hyperphosphorylation of tau. Multiple mechanisms of action can be associated with the neuroprotective effects of DHA and include antioxidant properties and activation of distinct cell signaling pathways. Although the first randomized clinical assays have yet failed to demonstrate convincing beneficial effects of DHA for AD patients, the knowledge gathered in recent years holds out a hope for prevention and suggests that the elderly and people bearing a genetic risk for AD should at least avoid DHA deficiency [72] . Julien et al., 2008 [73] suggest that high-fat consumption combined with low n-3 PUFA intake promote AD-like neuropathology. They report that consumption of a high-fat diet with a low n-3:n-6 PUFA ratio increased amyloid-beta (Abeta) 40 and 42 concentrations in detergent-insoluble extracts of parieto-temporal cortex homogenates from 3xTg-AD mice. Low n-3:n-6 PUFA intake ratio increased insoluble tau regardless of total fat consumption, whereas high-fat diet incorporating a low n-3:n-6 PUFA ratio also increased soluble tau compared to controls. In addition, Bousquet et al., 2008, [74] suggest that a high n-3 PUFA dietary intake exerts neuroprotective actions in an animal model of Parkinsonism. Yehuda et al., (1996) [75] used a mixture of omega-3 and omega-6 fatty acids in a ratio of 1:4 in a 4-week study of 100 AD patients and found improvements in mood, cooperation, appetite, sleep, short term memory and the ability to navigate in the home. In addition, Terano et al. (1999) [76] found a decrease in the severity of AD when subjects were supplemented for one year with 0.72 g DHA/day. There is also a case study reported that implicated Omega-3 fatty acids in the reversal of AD.
In 1990 Peers [77] reported a remarkable reversal of AD in a nursing home patient. The patient went from being restless and destructive and unable to dress himself to being calmer, regaining weight and was again able to dress himself. It appeared the reason for this totally unexpected improvement was that fish was served every week, which provided omega-3 fatty acids that had been almost totally absent in the patient's diet for at least five years before he was diagnosed with AD.
There is now additional evidence for the merits of omega-3 fatty acids and in particular fish oil for the treatment of late AD. Sears, 2002 [78] developed a protocol for treating terminal AD patients with very high doses of pharmaceutical grade fish oil-25 g/day. Twenty-five grams per day of fish oil is indeed a very high dose, and it is important that the oil be free of dangerous contaminants. The fish oil was combined with a diet based on Sears' Zone principles (moderate amounts of complex carbohydrates, low fat protein and monounsaturated fat) and fed using shakes that these patients could consume. Some patients went from being bed ridden and totally unable to take care of themselves to eating normally, playing cards, recognizing friends and family, and even going home to lead more or less normal lives. This author observed that the improvement was fish oil dose dependent, indicating that the omega-3 supplementation was probably responsible for the remarkable reversal of what is universally an irreversible decline until death. He also observed a positive, synergistic effect of the altered diet.
Thus following the AHA recommendations concerning omega-3 essential fatty acids for cardiovascular health should also have a positive effect on brain health. Food sources of omega-3 oils include fish, walnuts, flaxseeds, canola oil and socalled omega-3 eggs, where the chickens have been fed flaxseed. Fish oil provides the omega-3 fatty acids EPA and DHA, both of which can be made in the body from non-fish sources. However, the ability to synthesize these fatty acids from α-linolenic acid, the omega-3 fatty acid found in, for example, flax seed and nuts, may decline with age. Thus there may be a significant advantage associated with getting the required substances either from fish or fish oil. Yehuda et al., (2002) [75] discussed above provides one possible mechanism for these observations. It remains to be seen if an increase in neuronal membrane fluidity and a restoring of the aging neuronal membrane could be responsible for the action of fish oil in the reversal of late-stage AD.
Alpha-lipoic acid: Alpha-lipoic acid (LA), also known as thioctic acid, is a naturally occurring compound that is synthesized in small amounts by plants and animals, including humans [79] . Endogenously synthesized, LA is covalently bound to specific proteins, which function as cofactors for several important mitochondrial enzyme complexes. In addition to the physiological functions of protein-bound LA, there is increasing scientific and medical interest in potential therapeutic uses of pharmacological doses of free LA [80] .
LA contains two thiol (sulfur) groups, which may be oxidized or reduced (Figure 2 ). The reduced form is known as dihydrolipoic acid (DHLA), while the oxidized form is known as LA [81] . LA also contains an asymmetric carbon, meaning there are two possible optical isomers that are mirror images of each other (R-LA and S-LA). Only the R-isomer is endogenously synthesized and bound to protein. Free LA supplements may contain either R-LA or a 50/50 (racemic) mixture of R-LA and S-LA.
LA is found in a variety of foods, notably kidney, heart and liver meats as well as spinach, broccoli and potatoes. It is noted that although LA is found in a wide variety of foods from plant and animal sources, quantitative information on the LA or lipoyllysine content of food is limited and published databases are rather scarce.
LA has long been known as an essential cofactor for mitochondrial bioenergetic enzymes. Aside from its enzymatic role, in vitro and in vivo studies suggest that LA also acts as a powerful micronutrient with diverse pharmacologic and antioxidant properties.
Pharmacologically, LA improves glycemic control, polyneuropathies associated with diabetes mellitus, and effectively mitigates toxicities associated with heavy metal poisoning. As an antioxidant, LA directly terminates free radicals, chelates transition metal ions (e.g. iron and copper), increases cytosolic glutathione and vitamin C levels and prevents toxicities associated with their loss [80] .
When an antioxidant scavenges a free radical, it becomes oxidized itself and is not able to scavenge additional ROS or RNS until it has been reduced. DHLA is a potent reducing agent with the capacity to reduce the oxidized forms of several important antioxidants, including vitamin C and glutathione [82] . DHLA may also reduce the oxidized form of αtocopherol (the α-tocopheroxyl radical) directly or indirectly, by reducing the oxidized form of vitamin C (dehydroascorbate), which is able to reduce the alpha-tocopheroxyl radical [83] .
DHLA can also reduce oxidized forms of coenzyme Q 10 [84] which may also reduce the α-tocopheroxyl radical [85] .
Numerous researchers have demonstrated neuroprotective effects of LA. LA alone or in combination with other antioxidants such as L-carnitine has been found to improve measures of memory in animal models of age-associated cognitive decline, including rats [86, 87] , mice [88] and dogs [89] . However, it is not clear whether oral LA supplementation can slow cognitive decline related to aging or other pathology in humans. An uncontrolled, open-label trial in 9 patients with AD and related dementias, who were also taking acetylcholinesterase inhibitors, reported that oral supplementation with 600 mg/day of racemic LA appeared to stabilize cognitive function over a oneyear period [87] . However, the significance of these findings is difficult to assess without a control group for comparison.
Although studies in animals suggest that LA may be helpful in slowing age-related cognitive decline, randomized controlled trials are needed to determine whether LA supplementation is effective in preventing or slowing cognitive decline associated with age or neurodegenerative disease. Vitamin B 12 , B 6 and folic acid: Food sources of vitamin B 12 include milk products, meat, poultry, fish and spinach. Sources of folate include green leafy vegetables, beans and peas, grain products, tomatoes, oranges, beets, soybeans, fish and Vitamin B 6 is found in a wide variety of foods including fortified cereals, beans, meat, poultry, fish, and some fruits and vegetables [7] .
Elevated homocysteine levels are an independent risk factor for AD and dementia. This risk factor is closely related to vitamin B 12 and folic acid deficiencies. It can be argued that every adult should have their homocysteine blood level measured, and this is especially true for the elderly. For example, a level greater than 14 micromol/L nearly doubles the risk of AD in the elderly [90] .
Over the years, a number of studies, but not all have indicated that deficiencies in vitamin-B 12 , vitamin-B 6 and folic acid are related to elevated risk of dementia or AD [91, 92] . Several studies appear to confirm this. Wang et al., 2001 [93] found in a longitudinal study that the risk increased by two-fold when a serum cutoff of B12 < 150 pmol/L and folate < 10 nmol/L was compared to normal levels of both vitamins. An interesting three-fold increase in risk was found for a subgroup with good baseline cognition, and a similar pattern was seen with higher cut-off of 250 pmol/L and 12 nmol/L. Similar results were found by Clarke et al., [94] in a case-control study of total serum homocysteine, B 12 and folate and AD. For folate and B 12 serum levels the odds ratios obtained by comparing the upper with the lower third of the population were 3.3 and 4.3, respectively. Snowdon et al., 2000 [95] found in the Nun Study that low serum folate was strongly associated with atrophy of the cerebral cortex, particularly in persons with AD lesions seen at autopsy. These results, when considered with a number of other studies [93] , suggest a strong link to AD risk from low B 12 and folate and high homocysteine, being also an independent risk factor for AD. However, mechanistic details are far from clear since there are a number of potential ways in which low levels of vitamin B 12 could, lead to decreased cognition and AD [96] , and in fact, there may be multiple pathogenic mechanisms at work [97] . Therefore, monitoring the serum B 12 and folate concentration in the elderly appears important [93] .
High levels of homocysteine are treated effectively with B 12 , B 6 and folic acid. However, the interpretation of serum B 12 levels is not as simple. There appears to be a poor correlation between serum levels and tissue levels, and as such serum levels can fail to reveal a deficiency. Also, studies that relate serum levels to neuropsychiatric abnormalities or AD have used a variety of cut-off values which go well into the conventional, normal serum range, which suggests that the conventional "normal" cut-off is too low. A realistic cut-off of 300 pg/mL has been suggested. In addition, anemia that can be caused by a B 12 deficiency does not in general coexist with the neuropsychiatric abnormalities or AD, and thus the absence of anemia is not relevant in this context, but its presence is, since it is well known that anemia increases the risk of dementia [98] .
High homocysteine levels provide a fairly satisfactory marker for low B 12 and folate. If homocysteine levels are high, it seems reasonable that they should be treated aggressively until brought to normal. While many physicians would measure serum B 12 levels in patients presenting with cognitive or memory complaints, there is a problem when the results are "low normal," as well as a problem with the above mentioned issue with tissue vs. serum levels. It can be argued that since it is cheap, simple and safe, supplementation with B 12 is indicated in these cases simply to see if it produces an improvement in clinical symptoms. In this context, a study by Abyad, 2002 [98] is interesting in that he found the reversal of clinical symptoms among a group with cognitive dysfunction was most pronounced if they were treated early, with patients returning to normal if treated within three to six months, and poor results when treatment was initiated a year after the appearance of symptoms. This may explain why studies examining the reversal of dementia or cognitive impairment with B 12 therapy frequently yield poor results [99] .
Both oral and intramuscular administration has been shown to increase serum levels. An oral dose of 2 mg/day (not sublingual) was found to be as effective as 1 mg intramuscularly per month [100] . Some physicians start with more frequent injections. Multivitamins generally contain only very small amounts of B 12 . Sublingual oral administration circumvents some of the absorption problems.
Trehalose: Trehalose is a naturally occurring disaccharide with known protein and membrane stabilizing capability. Because of these unique chemical properties, this molecule has been the focus of study in several neurodegenerative diseases which are associated with the misfolding of disease-specific proteins. These conditions include AD an amyloid proteinopathy, Huntington's disease, an expanded polyglutamine proteinopathy, and oculopharyngeal muscular dystrophy, an expanded polyalanine proteinopathy.
In each disease, specific misfolded aggregate-prone proteins are resistant to the normal cellular processes of protein turnover and accumulate in insoluble inclusions in regions specific to each disease. While insoluble aggregates correlate with disease progression, there is increasing evidence that the initiating and most toxic events are caused by soluble protein oligimers or microaggregates. Trehalose is thought to work by interfering with production or enhancing destruction of toxic fragments. Trehalose benefit was first shown in Huntington's model systems Huntington's is an autosomal dominant neurodegenerative disease which presents with cognitive impairment, involuntary choreiform movements, and psychiatric manifestations [101] .
Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant disease that becomes present in the fifth or sixth decade of life with dysphagia, ptosis and proximal limb weakness. It is caused by an abnormal expansion of a polyalanine tract within the coding region of poly-A binding protein nuclear 1 (PAβPN1). This mutant protein demonstrates cellular pathology similar to Huntington's in that it forms aggregates. In OPMD, the culprit mutant protein forms aggregates in nuclei of skeletal muscle fibers, causing injury which culminates in cell dysfunction and death.
Trehalose has been found beneficial in transgenic model systems for this disease [102] . The authors have shown that trehalose reduces aggregate formation and prolongs viability in the cell model of this disease, and that it delays onset, ameliorates symptoms, and prolongs life in the mouse model of this disease.
A key event in AD pathogenesis is the conversion of the peptide beta-amyloid (Abeta) from its soluble monomeric form into various aggregated morphologies in the brain. Preventing aggregation of the peptide beta-amyloid is being actively pursued as a primary therapeutic strategy for treating AD. Trehalose, has been shown to be effective in preventing the deactivation of numerous proteins and in protecting cells against stress. Previous studies showed that trehalose is also effective in inhibiting aggregation of Abeta and reducing its cytotoxicity, although it shows differential effects toward Abeta40 and Abeta42. When co-incubated with Abeta40, trehalose inhibits formation of both fibrillar and oligomeric morphologies as determined by fluorescence staining and atomic force microscopy (AFM). However, when co-incubated with Abeta42, trehalose inhibits formation only of the fibrillar morphology, with significant oligomeric formation still present. When aggregated mixtures were incubated with SH-SY5Y cells, trehalose was shown to reduce the toxicity of Abeta40 mixtures, but not Abeta42. These results provide additional evidence that aggregation of Abeta into soluble oligomeric forms is a pathological step in AD and that Abeta42 in particular is more susceptible to forming these toxic oligomers than Abeta40. These results also suggest that the use of trehalose, a highly soluble, low-priced sugar, as part of a potential therapeutic cocktail to control Abeta peptide aggregation and toxicity warrant further study [103] .
Caffeine: Arendash et al., (2006) [104] have reported that five cups of coffee a day could protect humans in the same way that the caffeine equivalent appears to have in the study of mice.
In a controlled study experiment using Alzheimer's mice, one group of mice had caffeine added to their drinking water. The memory of mice who drank the caffeinated water was roughly similar to mice to had no Alzheimer's. They also found that levels of betaamyloid proteins reduced in mice that drank caffeine [104] .
Some interesting results were also obtained when researchers gave caffeine to aged Alzheimer's mice who already had high levels of beta-amyloid protein in their brains. It was discovered that caffeine reduced the levels of β-amyloid already present in the brain. This could suggest that coffee drinking is beneficial in people with AD but for the time being this is speculation.
The therapeutic effects of caffeine over the long-term have been noted in relation to reduced risk of type 2 diabetes, PD, cirrhosis of the liver, cancer of the liver, colorectal cancer and suicide. Although caffeine has been suspected of causing high blood pressure the association appears stronger when caffeine is consumed via soft drinks. They demonstrate that moderate daily intake of caffeine may delay or reduce the risk of AD. Ritchie et al., (2005) [105] observed that the psychostimulant properties of caffeine appear to reduce cognitive decline in women without dementia, especially at higher ages. Although no impact is observed on dementia incidence, further studies are required to ascertain whether caffeine may nonetheless be of potential use in prolonging the period of mild cognitive impairment in women prior to a diagnosis of dementia. Chen et al., 2008 [106] , concluded that chronic ingestion of caffeine protects against high cholesterol diet-induced increases in disruptions of the BBB and caffeine and drugs similar to caffeine might be useful in the treatment of AD. Wu et al., (2008) [107] , searched for all published English articles indexed in MEDLINE or PubMed from January 1966 to January 2008 and they findings do not support the hypothesis that coffee consumption increases the long-term risk of coronary heart disease. In contrast, habitual moderate coffee drinking was associated with a lower risk of CHD in women.
Ginkgo Biloba:
Ginkgo biloba is an herbal medicine which appears to enhance blood circulation and has antioxidant properties. Ginkgo has been used extensively in China and Europe for treating a wide range of conditions including memory and concentration problems, confusion, depression, anxiety, tinnitus and headaches as well as AD.
More than 40 components isolated from the ginkgo tree have been identified, but only two are believed to be responsible for the herb's beneficial effects in humans: flavonoids and terpenoids. Flavonoids (such as quercetin and rutin) have potent antioxidant effects.
Ginkgo preparations are of variable potency, and dose dependent studies are limited. Typical doses used in studies range from 40 to over 200 mg per day [108] . Ginkgo has been shown to increase the risk of bleeding in some people, and it can interact with aspirin, warfarin, and other medications. Thus it appears prudent to use it only under the supervision of a physician especially when large doses are contemplated. [109] . The mechanisms of action are thought to involve increasing blood supply by dilating blood vessels, reducing blood viscosity, modifying neurotransmitter systems and reducing the levels of oxygen free radicals [110] . There have been a number of recent studies, mostly double-blind, placebo-controlled and randomized, which examined the effectiveness of ginkgo on memory problems and delaying the onset of AD. However, the cellular and molecular mechanisms of the neuroprotective actions of ginkgo still remain largely unproved. One interesting aspect was presented in the Proceedings of the National Academy of Science [111] . This study indicated that ginkgo has an inhibitory effect of Aß aggregation and also influences an enzyme involved in the cell death signaling process, both of which could account for a neuroprotective effect. Andrieu et al., 2003 [112] examined the relationship between the use of ginkgo and other cerebral and peripheral vasotherapeutics and the onset of cognitive impairment. The results obtained after a 7-year follow-up indicated these treatments resulted in a significant drop in the risk of developing AD in elderly women.
In contrast, Solomon et al., [108] reported negative results for a memory enhancement trial with normal, healthy subjects. In the same line, some clinical studies of the use of extract of Ginkgo biloba available in Europe (EGb 761), have not shown a positive effect as a treatment for older people with mild to moderate dementia or age-associated memory impairment [112, 113] . Birks et al., (2002) [110] have made a detailed review of all the studies that met their standards for inclusion. When clinical global improvement was used as a criterion, benefits from the use of ginkgo were found. Benefits to cognition were also found, as well as benefits associated with activities of daily living and mood and emotional function. They found no significant differences between ginkgo and placebo in the proportion of individuals experiencing adverse effects.
In conclusion, there are no sufficient evidences of efficacy of Ginkgo in clinically significant benefits for people with dementia or cognitive impairment.
Panax Ginseng:
Ginseng is one of the most popular herbs worldwide. Ginseng has various medical applications, and it seems to have significant effects as a cognition-enhancing drug. Both American and Asian ginsengs belong to the species Panax and are similar in their chemical composition. Siberian ginseng or Eleuthero (Eleutherococcus senticosus), on the other hand, although part of the same plant family called Araliaceae, is an entirely different plant. Siberian ginseng does not contain ginsenosides, the active ingredients found in both Asian (Panax ginseng) and American ginseng (Panax quinquefolius). Luo et al., (2008) [111] , suggest that Panax ginseng is clinically effective in the cognitive performance of AD patient. Lee et al., (2008) [113] , showed good efficacy of Korean red ginseng (KRG) for the treatment of AD; however, further studies with larger samples of patients and a longer efficacy trial should be conducted to confirm the efficacy of KRG.
Recommended
multiple antioxidants for prevention: The levels of risk and protective factors in the brain may vary from one individual to another, depending upon the age, exposure to neurotoxins including free radicals, pharmacokinetics and consumption of diets or supplements rich in antioxidants [4] . Even though there is no direct link between diet and lifestyle related factors and the risk of PD and AD or progression of these diseases, it is always useful to include a balanced diet that contains low fat and plenty of fruits and vegetables rich in antioxidants.
Among fruits, blueberries and raspberries are particularly important because of their protective role against oxidative injuries in brain.
Lifestyle recommendations include daily moderate exercise, reduced stress and no tobacco smoking, avoiding exposure to pesticides, and avoiding the intake of iron, Cu, Mn and Zn through supplements. These recommendations are not specific to PD or AD, they are for general optimal health [4] .
Prevention strategies can be developed if the risk and protective factors for PD and AD are known. Based on current knowledge of risk and protective factors, we propose prevention strategies for those who have no clinical symptoms of PD or AD, and those who are at high risk for developing these neurological disorders. This involves a diet rich in antioxidants and moderate supplements with multiple antioxidants right from childhood that can maintain brain antioxidants at levels that are higher than normally provided by the nature.
Conclusions:
More researches are needed on their intracellular and molecular targets as special pathways underlying distinct functional ingredients induced neuroprotection. Long-term, prospective studies are recommended.
While the clinical value of antioxidants for the prevention of AD is often ambiguous, some can be recommended based upon: 1) epidemiological evidence, 2) known benefits for prevention of other maladies, and 3) benign nature of the substance.
A diet based on slowly digested carbohydrates, high fiber foods, whole grains, nuts, fruits and vegetables, fish, meat and red wine might provide protection against both CVD and dementia. Fruits, especially berries, and green, leafy vegetables provide a wide spectrum of antioxidants. A combination of dietary regimen of low total calorie and rich antioxidant nutrients and maintaining physical and intellectual activities may ultimately prove to be of the most efficacious strategies for neurodegenerative diseases prevention.
